Chronic widespread pain (CWP) is a significant burden in communities. Understanding the impact of population-dependent (e.g., age, gender) and contextual-dependent (e.g. survey method, region, inequality level) factors have on CWP prevalence may provide a foundation for population-based strategies to address CWP. Therefore, the purpose of this study was to estimate the global prevalence of CWP and evaluate the population and contextual factors associated with CWP. A systematic review of CWP prevalence studies in the general population was undertaken. Meta-analyses were conducted to determine CWP prevalence, and study population data and contextual factors were evaluated using a meta-regression. Thirty-nine manuscripts met the inclusion criteria. Study CWP prevalence ranged from 1.4% to 24.0%, with CWP prevalence in men ranging from 0.8% to 15.3% and 1.7% to 22.1% in women. Estimated overall CWP prevalence was 9.6% (8.0-11.2%). Meta-regression analyses showed gender, United Nations country development status, and human development index (HDI) influenced CWP prevalence, while survey method, region, methodological and reporting quality, and inequality showed no significant effect on the CWP estimate. Globally CWP affects one in ten individuals within the general population, with women more likely to experience CWP than men. HDI was noted to be the socioeconomic factor related to CWP prevalence, with those in more developed countries having a lower CWP prevalence than those in less developed countries. Most CWP estimates were from developed countries, and CWP estimates from countries with a lower socioeconomic position is needed to further refine the global estimate of CWP. Significance: This systematic review and meta-analysis updates the current global CWP prevalence by examining the population-level (e.g. age, gender) and contextual (e.g. country development status; survey style; reporting and methodologic quality) factors associated with CWP prevalence. This analyses provides evidence to support higher levels of CWP in countries with a lower socioeconomic position relative to countries with a higher socioeconomic position.
Introduction
The estimated prevalence of chronic pain, defined as pain lasting more than 3 months, is between 35% and 50% worldwide (Elzahaf et al., 2012) . Epidemiological studies of chronic pain have tended to centre on one joint, such as the foot, knee, low back and shoulder (Freburger et al., 2009; Hiller et al., 2012; Hurley et al., 2012; Roh et al., 2012) . However, some individuals experience pain all over the body, and in 1990, the term 'chronic widespread pain' (CWP) was defined as pain lasting longer than 3 months, with pain being on the left and right sides of the body, above and below the waist, and on the axial skeleton (Wolfe et al., 1990) . With the formal 1990 definition of CWP, a recent review suggested the worldwide estimate of CWP ranges from 10.6% to 11.8% (Mansfield et al., 2016) .
Chronic widespread pain adversely affects quality of life, mobility and physical function (Nicholl et al., 2009) . Furthermore, CWP is a common condition associated with fibromyalgia syndrome (FMS) and is noted to be an early indicator of FMS (Forseth et al., 1999; Toda, 2011) . CWP and FMS can place significant challenges onto the healthcare system, and inconsistent messages exist within the literature with regard to the most effective diagnosis and management strategies (Lee et al., 2014) . Living with CWP can have significant cost implications to not only the government but also the individual patient in terms of lost work, benefits and medical costs (Barham, 2012; Gaskin and Richard, 2012; Henschke et al., 2015) . In Europe approximately 1.5-3.0% of their annual gross domestic product (GDP) is spent on chronic pain (Barham, 2012; Gaskin and Richard, 2012) . In the United States (US), chronic pain costs between $560 and $635 billion annually, a cost higher than heart disease ($309b), cancer ($243b) and diabetes ($188b). Further, direct and indirect annual costs of CWP per patient in the United States are estimated to be $12,428 (Schaefer et al., 2015) .
Since the inception of the ACR definition in 1990, researchers have estimated CWP at the local and country level in order to determine burden of CWP in the population (Mansfield et al., 2016) . While this prior study of global CWP prevalence addressed a significant gap, the current review and analyses aims to build upon it to update the CWP estimate and to evaluate study population (e.g. age, gender) and contextual (e.g. country development status; survey style; methodology and reporting quality) factors associated with CWP prevalence.
Methodology 2.1 Search strategy
A primary literature search of electronic databases was performed to extract epidemiological studies of the global prevalence of chronic widespread pain (CWP) in the general adult population (1st January 1990 to 5th April 2017). The lower year limit of 1990 was applied to align with the seminal publication defining CWP (Wolfe et al., 1990) .
Electronic databases included in the study were PSYCinfo, MEDLINE, Cumulative Index to Nursing and Allied Health Literature (CINAHL), The Allied and Complementary Database (AMED), Cochrane library, PubMed and OVID. To identify publications related to the prevalence of CWP, there were three criterion components of the search strategy: (1) outcome, (2) methodology, and (3) population, which were combined using Boolean operators. Outcome search terms were associated with 'chronic pain,' and methodology search terms were associated with 'prevalence,' and to limit the likelihood of sub-populations a 'NOT' operator of 'cancer' or 'diabetes' was used to reduce publications that were not focused on the general population (Supporting information Figure S1 ). No language restrictions were applied.
Selection criteria and data extraction
Set inclusion and exclusion were specified a priori and applied in three steps (Table 1 ). In the first step, studies were eliminated if it was evident from the title that criteria regarding outcome, methodology and population were not satisfied. At this title stage, one reviewer (PA) eliminated publications, with a second reviewer (JLR) verifying these results. In the second step, two reviewers (PA and JLR) independently reviewed abstracts to determine if inclusion criteria were met. From the abstract stage, full-texts of the manuscripts were obtained and reviewed for inclusion, with study methods evaluated against the set criteria. Manuscripts written in languages other than English were included and were reviewed by others comfortable with the language. Prevalence data were recorded for CWP in the general population along with separate figures for gender and age as well as weighted and unweighted where applicable. If data from the same manuscript were reported in multiple publications, data are reported as one study.
Assessment of study quality
Two reviewers (JLR and PA) independently evaluated the included studies based on the criteria in the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist (Von Elm et al., 2007) , a reliable method for reporting observational studies (Tate and Douglas, 2011) . For this analysis, the STROBE was modified to include 12 items. Each item was scored independently as either 'Identified' (1 point) or 'Not Identified' (0 point), and scoring was discussed to reach consensus. The points from the modified STROBE were summed (Supporting Information Table S1 ), and studies were considered as having low risk of bias if they were found to be of high quality (≥9/12) and high risk of bias if they were found to be of low quality (≤8/12), with this cutpoint near the 80% quality cut-point (Slavin, 1995) .
CWP study contextual data
Additional contextual data were added to evaluate factors associated to the CWP prevalence. Contextual data included were the country's United Nations (UN) development status (i.e. developed and developing country) (UN 2012), World Health Organisation (WHO) region (WHO 2017), Human Development Index (HDI) (HDR 2016) and Gini index (TWB 2017) .
The HDI is a composite measure of three basic dimensions: life expectancy, education, and per capita income, and it is an indicator of the country's support systems and its citizen's health, personal, social, and political freedom, and well-being. The GINI index is a measure of statistical dispersion used to represent the net income distribution within a country, and it can define a country's level of richto-poor inequality. GINI index values can range between 0 and 1, with 0 representing perfect equality and 1 representing perfect inequality, but in practice, it ranges from approximately 0.2 to 0.7 (TWB 2017). The HDI and Gini values and the country's development status were based on the year of the data collection, and when an estimate was not available for the study year, the closest year to the study collection period was used.
Data analysis
A meta-analysis combined the CWP prevalences of the individual studies to estimate the prevalence of CWP for the overall population sample as well as by gender, age, WHO region and survey method. Univariate meta-analyses were performed on all individual and contextual variables to determine if there was a significant effect of the variable on CWP prevalence. Statistical significance was set to p < 0.05. There was no multiple testing correction, which may increase the likelihood of false positive; however, it is a valid means for exploring value of each variable in regression modelling (Bender and Lange, 2001) . I 2 statistical calculations were conducted to examine the heterogeneity between all studies and subgroups. The 95% confidence intervals were calculated using the Wilson score method with continuity corrections. All statistical analyses were performed using R version 3.3.1.
Results

Study selection
Implementation of the search strategy yielded 12,097 records, of which 5768 were duplicates (Fig. 1) Included studies had a publication date after 1 January 1990, aligning with the seminal publication defining chronic widespread pain (CWP) (Wolfe et al., 1990) ; however studies did not need to use this definition Study participants Studies were included when most participants were deemed to be 'adult'. As the definition of 'adult' can vary by country, for this analysis to be include studies had to include participants over 18 years of age Outcome measures CWP definition had to align to the working definition by Wolfe et al. (1990) , but it did not necessarily have to be this definition. CWP had to encompass multiple regions of the body, even if noted as 'generalized pain throughout' and had to query pain that had lasted at least 1 month or more to be noted as 'chronic' to be included. Studies using the Manchester and study determined criteria, where pain must also be in at least two contralateral limbs and in the axial skeleton were included. Studies that evaluated pain in the past week or studies that only focused on specific regions within the body were excluded Analysis Data presented had to include CWP prevalence in population studied estimates) with a total of 632,937 participants. Study sample size ranged from 361 (Santos et al., 2010) to 501,733 (Walker-Bone et al., 2016) . Twenty-six studies included both genders, whereas three studies included only women (Abusdal et al., 1997a,b; Schochat and Beckmann, 2003; Topbas et al., 2005) and one study included only men (Macfarlane et al., 2009b; Lee et al., 2010) . Six studies failed to report gender characteristics (Wolfe et al., 1995; Lindell et al., 2000; Bergman et al., 2001; Papageorgiou et al., 2002; Hagen et al., 2005; Scudds et al., 2006; Gerdle et al., 2008) . Participants' age in the included studies ranged from 15 to 94 years.
Study characteristics
Country CWP prevalence data (Table 2) is from the United Kingdom (N = 9) (Croft et al., 1993; Hunt et al., 1999; Macfarlane et al., 1999 Macfarlane et al., , 2009a Benjamin et al., 2000; Papageorgiou et al., 2002; Carnes et al., 2007; Lee et al., 2010; Pang et al., 2010; Vandenkerkhof et al., 2011; Choudhury et al., 2013; Fl€ uß et al., 2015; Walker-Bone et al., 2016) , Spain (N = 4) (Mas et al., 2008; Bannwarth et al., 2009; Macfarlane et al., 2009b; Branco et al., 2010; Lee et al., 2010; Dueñas et al., 2015 Dueñas et al., , 2016 , Brazil (N = 3) (Assumpc ßão et al., 2009; Santos et al., 2010; Cabral et al., 2014) , Sweden (N = 4) (Lindell et al., 2000; Bergman et al., 2001; Gerdle et al., 2008; Macfarlane et al., 2009b; Lee et al., 2010; Dragioti et al., 2016) , United States (N = 2) (Wolfe et al., 1995; Riskowski, 2014) , France (N = 2) (Bannwarth et al., 2009; Branco et al., 2010; Perrot et al., 2011) , Germany (N = 2) (Schochat and Raspe, 2003; Bannwarth et al., 2009; Branco et al., 2010) , Israel (N = 2) (Buskila et al., 2000; Ablin et al., 2012) , Italy (N = 2) (Bannwarth et al., 2009; Macfarlane et al., 2009b; Branco et al., 2010; Lee et al., 2010) , Norway (N = 2) (Abusdal et al., 1997a,b; Hagen et al., 2005) , Belgium (N = 1) (Macfarlane et al., 2009b; Lee et al., 2010) , Canada (N = 1) (White et al., 1999) , Estonia (N = 1) (Macfarlane et al., 2009b; Lee et al., 2010) , Hong Kong (N = 1) (Scudds et al., 2006) , Hungary (N = 1) (Macfarlane et al., Figure 1 Flow chart of included studies.
2009b; Lee et al., 2010) , Netherlands (N = 1) (Picavet and Schouten, 2003) , Poland (N = 1) (Macfarlane et al., 2009b; Lee et al., 2010) , Portugal (N = 1) (Bannwarth et al., 2009; Branco et al., 2010) and Turkey (N = 1) (Topbas et al., 2005) . The included studies varied in terms of CWP definition, survey method and measurement processes (Supporting Information Table S2 ). CWP was identified using the ACR criteria (N = 24) (Wolfe et al., 1990) , the Manchester definition (N = 3), and a study-specific definition (N = 5). CWP data were collected by postal survey (N = 10) (Croft et al., 1993; Abusdal et al., 1997a,b; Lindell et al., 2000; Bergman et al., 2001; Papageorgiou et al., 2002; Picavet and Schouten, 2003; Hagen et al., 2005; Carnes et al., 2007; Gerdle et al., 2008; Fl€ uß et al., 2015; Dragioti et al., 2016) , telephone (N = 1) (Dueñas et al., 2015 (Dueñas et al., , 2016 face-to-face interviews (N = 2) (Mas et al., 2008; Cabral et al., 2014) , clinical examination (N = 1) (Santos et al., 2010) , touch screen questionnaire (N = 1) (Walker-Bone et al., 2016) or combined methods (N = 15) (Wolfe et al., 1995; Hunt et al., 1999; Macfarlane et al., 1999 Macfarlane et al., , 2009a White et al., 1999; Benjamin et al., 2000; Buskila et al., 2000; Schochat and Raspe, 2003; Topbas et al., 2005; Scudds et al., 2006; Assumpc ßão et al., 2009; Bannwarth et al., 2009; Branco et al., 2010; Lee et al., 2010; Pang et al., 2010; Perrot et al., 2011; Vandenkerkhof et al., 2011; Ablin et al., 2012; Choudhury et al., 2013; Riskowski, 2014) .
Chronic widespread pain prevalence
The included 30 studies provided 41 prevalence estimates of CWP. From the included manuscripts, overall CWP sample prevalence, ranged from 1.4% in the United Kingdom (Walker-Bone et al., 2016) to 24.0% in Brazil (Assumpc ßão et al., 2009). In combining the studies where sample prevalence data was available and excluding any studies with single gender analysis, a total of 622,169 participants across 26 studies were included in the analysis, and the estimated overall CWP prevalence was 9.6% [95% confidence interval (CI): 8.0-11.2%].
Gender
Four studies were of a single gender, one of men only (Macfarlane et al., 2009b; Lee et al., 2010) and three of women only (Abusdal et al., 1997a,b; Schochat and Raspe, 2003; Topbas et al., 2005) , while 11 studies provided estimates from both genders in the general population. In the single gender studies, CWP prevalence in men was estimated at 8.3%, with data only available from a CWP study in Europe (Macfarlane et al., 2009b; Lee et al., 2010) , while in women CWP prevalence ranged from 13.5% in Germany (Schochat and Raspe, 2003) to 22.1% in Norway (Abusdal et al., 1997a,b) . When combining women-only studies (n = 6805), the CWP prevalence in women was 17.3% (16.4-18.1%).
Where studies included data for both genders, the prevalence in men ranged from 0.8% in Sweden (Dragioti et al., 2016) to 15.3% in Estonia (Macfarlane et al., 2009b; Lee et al., 2010) , and in women it ranged from 1.7% (Walker-Bone et al., 2016) to 15.6% (Croft et al., 1993) , with both study CWP estimates coming from the United Kingdom. When combining the data for men (n = 242,808), the estimated overall CWP prevalence was 7.2% (5.5-8.9%), while in women, (n = 291,129) the estimated overall CWP prevalence was 11.2% (8.3-14.2%). Univariate regression analysis by gender found that women had a significantly higher CWP prevalence relative to men (p < 0.01; Table 3 ).
Age
Age-specific data were provided in 14 studies (Croft et al., 1993; Abusdal et al., 1997a,b; Hunt et al., 1999; Macfarlane et al., 1999 Macfarlane et al., , 2009b Benjamin et al., 2000; Buskila et al., 2000; Lindell et al., 2000; Bergman et al., 2001; Picavet and Schouten, 2003; Carnes et al., 2007; Gerdle et al., 2008; Mas et al., 2008; Bannwarth et al., 2009; Branco et al., 2010; Lee et al., 2010; Dueñas et al., 2015 Dueñas et al., , 2016 Dragioti et al., 2016; Walker-Bone et al., 2016) . Due to the variability in each of the available studies' age bandings it was not possible to combine the data for further analysis. Of studies evaluating CWP by age, nine reported an increase in pain prevalence with age (Croft et al., 1993; Abusdal et al., 1997a,b; Hunt et al., 1999; Macfarlane et al., 1999; Benjamin et al., 2000; Buskila et al., 2000; Lindell et al., 2000; Bergman et al., 2001; Picavet and Schouten, 2003; Gerdle et al., 2008; Dueñas et al., 2015 Dueñas et al., , 2016 , while four reported a decrease or levelling out of pain prevalence from 50 to 60 years only to increase again from 60 years (Croft et al., 1993; Mas et al., 2008; Macfarlane et al., 2009b; Lee et al., 2010; Dragioti et al., 2016) .
Survey method
Methods of data collection varied between studies, with 16 studies using a single style of data collection (i.e. telephone, face-to-face or clinical/physical exam) and fourteen using a combined method (postal or telephone with clinical/physical Macfarlane et al., 1999; Benjamin et al., 2000) Ge. 7.5 (7.3-7.7) It.
9.8 (9.5-10.5) Po. 5.1 (4.8-5.4) Sp. examination). The method of survey was further grouped into a personal (face-to-face, telephone and clinical examination) and non-personal (postal survey) approach for further analysis. Seventeen studies with 21 CWP estimates (n = 546,553) were included in the personal group, while nine studies (n = 75,616) were included in the non-personal survey method. Random-effects CWP prevalence estimates between personal and non-personal were similar [9.9% (7.5-12.3%) vs. 7.6% (4.7-10.4%,), p = 0.981].
Region
By WHO regions (Fig. 2 
Development status, HDI Index and GINI Index
Contextual factors of socioeconomic position included the UN development status, HDI and GINI Index. Based on the country's UN development status, there were 27 CWP estimates (n = 620,214) from developed countries, and the CWP prevalence of 8.6% (6.9-10.3%). Three CWP estimates were from developing countries (n = 1955), and the CWP prevalence estimate for these countries was 14.5% (3.9-25.1%). The meta-regression showed UN development status relating to CWP prevalence (p = 0.041), which was similar to the HDI results that countries with a higher the HDI (i.e. more developed country) had a lower reported CWP prevalence (p = 0.001).
Methodological quality
Quality scores ranged from 6/12 to 12/12 (Supporting Information Table S3 ), with 10 manuscripts being noted as having low quality (≤8/12) (Abusdal et al., 1997a,b; White et al., 1999; Papageorgiou et al., 2002; Picavet and Schouten, 2003; Scudds et al., 2006; Gerdle et al., 2008; Pang et al., 2010; Perrot et al., 2011; Vandenkerkhof et al., 2011) and 29 of high quality (≥9/12) (Croft et al., 1993; Wolfe et al., 1995; Hunt et al., 1999; Macfarlane et al., 1999 Macfarlane et al., , 2009a Benjamin et al., 2000; Buskila et al., 2000; Lindell et al., 2000; Bergman et al., 2001; Schochat and Raspe, 2003; Hagen et al., 2005; Topbas et al., 2005; Carnes et al., 2007; Mas et al., 2008; Assumpc ßão et al., 2009; Bannwarth et al., 2009;  'Studies' refer to number of manuscripts, while 'Estimates' relate to the number of countries within a manuscript that provided CWP prevalence estimates. HDI, Human Development Index; Inc, Including gender specific analysis; exc, excluding the gender specific analysis; UN, United Nations; WHO, World Health Organisation. Figure 2 Geographical spread of CWP prevalence. Branco et al., 2010; Lee et al., 2010; Santos et al., 2010; Ablin et al., 2012; Choudhury et al., 2013; Cabral et al., 2014; Riskowski, 2014; Dueñas et al., 2015 Dueñas et al., , 2016 Fl€ uß et al., 2015; Dragioti et al., 2016; Walker-Bone et al., 2016) . Most of the included manuscripts (n = 37) consistently identified the CWP outcome measure and study eligibility criteria. Lack of appropriate reporting was in reporting bias and providing detailed methodology. When addressing bias, only five manuscripts identified their methods for controlling bias, 18 failed to provide their adjusted estimates and precision (e.g. 95% confidence interval) for CWP prevalence, and 27 did not report data collection methods and participant recruitment. The high-quality studies (n = 592,034) had a CWP prevalence of 9.7% (7.4-12.1%), while the low-quality studies (n = 30,135) had a similar (p = 0.242) CWP prevalence estimate of 7.5% (5.3-9.6%).
Discussion
The current review aimed to determine the global prevalence of CWP in the general population. The review identified 30 studies with 41 estimates of CWP prevalence. From these CWP studies, global CWP prevalence estimate was 9.6% (95% CI: 8.4-11.2%). Women were found to have a higher CWP prevalence than men (11.2% vs. 7.2%). In identifying other factors associated with CWP prevalence, data collection style of personal or non-personal approach showed no significant effect, but the personal approach (i.e. face-to-face, telephone, examination) tended to increase CWP prevalence compared to non-personal (9.9% vs. 7.6%). Additionally, countries with a higher human development index (HDI) had a lower CWP prevalence compared to lower HDI countries (8.6% vs. 14.5%).
Results from this work suggest there is a significant burden of CWP on the general population, particularly among women, and that improving a country's standard of living, as indicated by the HDI, may influence CWP prevalence.
Diagnostic criteria
Chronic widespread pain diagnosis originally came from the ACR 1990 criteria of FMS. However, recently the Manchester criteria, which requires pain to be found in two locations of two contralateral limbs and also in the axial skeleton (Okifuji and Hare, 2014) , is gaining traction. Although, the ACR 1990 and Manchester definitions allow standardization and comparisons to be made (Okifuji and Hare, 2014) , results of CWP prevalence by these two definitions are not similar. Gerdle et al. (Gerdle et al., 2008) found CWP to be 7.4% when applying the Manchester criteria, while they only recorded 4.8% with ACR. In contrast the Manchester cohort Macfarlane et al., 1999; Benjamin et al., 2000) found CWP to be 4.7% with the Manchester criteria and 12.9% with the ACR definition. Between these studies sample sizes were different [n = 1953 [n = (Hunt et al., 1999 Macfarlane et al., 1999; Benjamin et al., 2000) vs. n = 7637 (Gerdle et al., 2008) ], but these two studies also differed in the number of pain sites the study participant could select in the pain chart. The Manchester group Macfarlane et al., 1999; Benjamin et al., 2000) had 26 pain sites available versus 17 in the Gerdle et al. study (Gerdle et al., 2008) . The number of pain sites available to select could not only lead to participant confusion, but it could also lead to participants under or overreporting the number of pain site depending on if their specific pain site is not provided. Research evaluating style of pain reported has suggested that the most efficient method for assessing this is through the completion of a body manikin (Croft, 2002) or through the number of pain sites rather than the location of pain (Beasley and Macfarlane, 2014) , which is what the ACR 2010 definition does. As such, future research should aim to determine a uniform diagnosis for CWP that utilizes a body manikin with a set number of pain sites to ensure prevalence figures are reliable and can be comparable across studies.
Age and gender
The current review found no significant difference in CWP by age group. However, part of the lack of effect may be due to few studies reporting CWP prevalence by similar age group bandings. Given the inconsistencies in age group reporting it is difficult to determine accurate CWP prevalence estimates, and future studies should aim to report specific prevalence estimates for age using consistent age banding. Studies have consistently shown that women experience more pain than men (Fillingim et al., 2009; Bartley and Fillingim, 2016; Pieretti et al., 2016) . This review found similar results, with the meta-analysis showing CWP was higher in women compared to men (11.4% vs. 7.2%). Reasons for the gender differences in pain are often hypothesized to be biological, but studies have also suggested that differences in pain may relate to psychological or social factors (Wiesenfeld-Hallin, 2005) as some men may fear they will appear weak if they express their pain (Fillingim et al., 2009) . Researchers hypothesize that while women score higher on pain, they are often encouraged to talk about their feelings and may be more comfortable than men at indicating that they are experiencing pain (Fillingim et al., 2009 ).
Geographical region
Although there were no regional variations of CWP prevalence as noted by the meta-regression, these results should be viewed with caution, as regions other than Europe and the Americas were not wellrepresented. The prior CWP review (Mansfield et al., 2016) noted differences between Europe and America, with Europe having a higher CWP prevalence than the Americas (12.8% vs. 7.1%). These prior results are in contrast with the current study where it shows a non-significant difference between regions (8.9% in Europe vs. 10.9% in Americas). A possible explanation for this CWP difference could be the variation in the studies included between the two reviews. For example, this review included only general population studies, not studies of specific populations within the larger population. As such, the prior meta-analysis (Mansfield et al., 2016 ) included a CWP study of a Native American population (Jacobsson et al., 1996) , a small sub-population within the US general population, but did not include a large population-based National Health and Nutrition Examination Survey (NHANES) study (Riskowski, 2014) , suggesting the current and prior CWP systematic review focused on different study populations.
Socioeconomics position and CWP
The novelty of this meta-analysis was in the analyses of socioeconomic position measures to CWP prevalence. The socioeconomic position contextual factors were the HDI (HDR 2016), United Nations (UN) developed/developing country definition (UN 2012) and GINI index (HDR 2016) . Although the HDI and UN definition of developed/developing countries may appear similar, the HDI is a composite index based on life expectancy, education level and per capita income indicators, whereas the UN definition of developed and developing countries is 'intended to reflect basic economic country conditions' rather than consideration of life within the country (United Nations United Nations Department of Economic and Social Affairs (US DESA) 2012).
Within the work presented, the dichotomized UNdefined developed versus developing country showed higher CWP prevalence within the developing countries (p = 0.04). The results of less developed countries having greater prevalence of CWP aligned to results of the continuous HDI variable, which showed countries with a higher HDI (more developed countries) having a lower CWP prevalence. The results of a higher HDI (e.g. developed countries) associated with lower prevalence of pain aligns with other studies evaluating socioeconomic position with chronic pain (Urwin et al., 1998) and adds further evidence that socioeconomic position is associated with health (Braveman et al., 2010) and pain (Riskowski, 2014) .
Studies have suggested that financial strain and lower socioeconomic conditions can result in stressinduced muscular tension and pain (Soares and Jablonska, 2004 ). At the individual-level, poor coping strategies to stress, leading to muscular tension, is believed to play a role in the higher rates of chronic pain in those in a lower socioeconomic position relative to their higher counterparts (Ridder De, 2000; Roth and Geisser, 2002) . Extrapolating the individual-level measure of socioeconomic position to the contextual population-level measure (e.g. HDI), poor community and support structures that provide mechanisms to assist people in coping with stress may explain the population-level association of CWP to lower socioeconomic conditions. Given the low number of studies from developing and lower socioeconomic countries, there is a need for epidemiological studies of chronic pain in these regions to determine the global prevalence of CWP and to evaluate the effect of the country's socioeconomic position with respect to CWP prevalence.
Strengths and limitations
Although there is a relatively recent review examining global prevalence of CWP (Mansfield et al., 2016) , this review adds to their results by examining a number of contextual factors that may impact the CWP prevalence, such as the HDI, survey method, and WHO region. However, other factors not accounted in this review were race and ethnicity, due to the lack of reported data. Future studies, where appropriate, should include race and ethnicity information of participants as some studies have suggested it may impact risk of CWP (Allison et al., 2002; Macfarlane et al., 2005) . Along these same lines, studies have also suggested that class or socioeconomic position may also be an individual factor that relates to risk of chronic pain (Urwin et al., 1998; Rios and Zautra, 2011) , but within the systematic review there was one study that evaluated CWP by class or social position. Thus, the surrogate markers of HDI and the WHO development status were used to evaluate the effect of social deprivation at the country-level, with results suggesting that with greater social deprivation there is greater risk of CWP. However, the country-level marker may not truly represent the participants in the study, and future work should evaluate health status along social strata in addition to racial and ethnic categories (Braveman et al., 2010) .
Conclusion
Results of this systematic review indicate that CWP affects one in ten individuals globally within the general population. In 30 studies across 19 countries women were found to have a higher CWP prevalence than men, and those in countries with a lower HDI tended to be more likely to experience CWP than those in a high HDI country. To further evaluate CWP, research is needed by other individuallevel factors (e.g. race, ethnicity) with a greater range of developing and developed countries.
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